The document summarizes an external quality assessment program for colorectal carcinoma focused on testing mutations in KRAS, NRAS, and BRAF genes. The program is accredited according to ISO/IEC 17043 and run by SEKK s.r.o. In each of two rounds, participants will receive samples containing sections from five tumors and test for mutations, with assigned values determined by expert laboratories. Participants will receive individual reports and the program will issue public summaries.
The document summarizes an external quality assessment program for colorectal carcinoma focused on testing mutations in KRAS, NRAS, and BRAF genes. The program is accredited according to ISO/IEC 17043 and run by SEKK s.r.o. In each of two rounds, participants will receive samples containing sections from five tumors and test for mutations, with assigned values determined by expert laboratories. Participants will receive individual reports and the program will issue public summaries.
The document summarizes an external quality assessment program for colorectal carcinoma focused on testing mutations in KRAS, NRAS, and BRAF genes. The program is accredited according to ISO/IEC 17043 and run by SEKK s.r.o. In each of two rounds, participants will receive samples containing sections from five tumors and test for mutations, with assigned values determined by expert laboratories. Participants will receive individual reports and the program will issue public summaries.
European Society of Pathology Quality SEKK s.r.o. Assurance Foundation Arnosta z Pardubic 2605, 530 02 Pardubice Barastraat 6, 1070 Brussels, Belgium Czech Republic www.esp-pathology.org www.sekk.cz
Programme description Samples
The programme is focused on external quality In each round the participant receives 1 set of assessment of the testing of mutations of the samples containing 15 unstained FFPE sections clinically most important genes relevant to anti- obtained from 5 primary samples (invasive EGFR therapy in colorectal carcinoma - KRAS, colorectal adenocarcinomas). NRAS, BRAF. Participants are expected to Every participant receives 3 sections of each identify and describe mutations and they can primary sample. One section is to be used for choose any combination of KRAS, NRAS, BRAF hematoxylin-eosin (HE) staining and the testing. remaining 2 sections for DNA isolation and Accreditation mutation detection. The CRC programme is accredited according to Assigned values the international standard ISO/IEC 17043. The mutations that are expected to be found by the participants (assigned values) are ISO/IEC 17043 determined by a consensus of 3 European accredited programme expert laboratories.
Programme homepage Evaluation and reports
Each round is evaluated separately and The homepage of the CRC programme, which independently. The output of the evaluation collects all information belonging to this process consists of 2 parts: programme in one place, is: Public summary (statistics and supervisor’s www.sekk.cz/CRC comment) freely available to everybody. Schedule Individual (private) reports for each The programme consists of 2 rounds: participant. round 1 starts on April 3, 2023 Please find examples at the CRC programme round 2 starts on August 22, 2023 homepage. Participation in both rounds is required. The How to participate application deadline is February 1, 2023. A step-by-step guide on how to register and In each round the participants have 4 weeks to order online is available here: analyse the samples. http://www.sekk.cz/eqa/2023_how_to_order.pdf Annual fee Contacts The annual fee that covers complete services Feel free to contact us if you have any questions (participation in 2 rounds, samples, transport of or requests at sekk@sekk.cz the samples to the participant’s laboratory, evaluation) is 470 EUR.